Amphastar Pharmaceuticals (AMPH) Stock Rating Upgraded by Zacks Investment Research

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday. The brokerage currently has a $22.00 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.58% from the stock’s current price.

According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “

Several other analysts have also recently issued reports on the company. Raymond James Financial cut Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a report on Thursday, November 9th. BMO Capital Markets upped their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Friday, November 10th. BidaskClub cut Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Needham & Company LLC upped their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Finally, Jefferies Group set a $19.00 target price on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $19.67.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) remained flat at $$19.37 during trading hours on Tuesday. 113,600 shares of the company’s stock were exchanged, compared to its average volume of 180,157. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $891.47, a PE ratio of 129.13, a PEG ratio of 1.36 and a beta of 1.69. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS. equities analysts predict that Amphastar Pharmaceuticals will post -0.03 EPS for the current fiscal year.

In other news, Director Stephen B. Shohet sold 7,862 shares of the company’s stock in a transaction on Thursday, October 26th. The stock was sold at an average price of $18.39, for a total value of $144,582.18. Following the transaction, the director now owns 31,978 shares of the company’s stock, valued at approximately $588,075.42. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO William J. Peters sold 6,226 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,264 shares of company stock worth $1,350,119. Corporate insiders own 11.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after purchasing an additional 842 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $111,000. Municipal Employees Retirement System of Michigan lifted its stake in shares of Amphastar Pharmaceuticals by 58.8% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after purchasing an additional 4,960 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Amphastar Pharmaceuticals by 70.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock worth $321,000 after acquiring an additional 7,401 shares in the last quarter. Finally, Thrivent Financial For Lutherans lifted its stake in Amphastar Pharmaceuticals by 7.2% during the 2nd quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock worth $386,000 after acquiring an additional 1,460 shares in the last quarter. 44.00% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/23/amphastar-pharmaceuticals-amph-stock-rating-upgraded-by-zacks-investment-research.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply